FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileErnexa Therapeutics Inc. Warrants
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ERNAW
Ernexa Therapeutics Inc. Warrants Stock AnalysisComprehensive stock analysis for Ernexa Therapeutics Inc. Warrants (ERNAW) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisERNAW
ERNAW
Ernexa Therapeutics Inc. Warrants
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ERNAW
  1. Home
  2. Stocks
  3. Ernexa Therapeutics Inc. Warrants

Ernexa Therapeutics Inc. Warrants

🇺🇸ERNAW•NASDAQ

Ernexa Therapeutics Inc. Warrants

🇺🇸ERNAW•NASDAQ
Market cap
$201.82K

Your view on ERNAW

Mkt Cap
$201.82K
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Ernexa Therapeutics Inc. Warrants

Industry
Biotechnology
Sector
Healthcare
CEO
Sanjeev Luther
Headquarters
1035 Cambridge Street, Cambridge, MA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Sanjeev Luther
Headquarters
1035 Cambridge Street, Cambridge, MA, US
Description

Operating in the preclinical phase, Ernexa Therapeutics Inc. is dedicated to advancing therapies based on induced mesenchymal stem cells (iMSC) to combat both solid tumors and autoimmune conditions.

Its primary therapeutic, ERNA-101, is an allogeneic iMSC specifically formulated to secrete pro-inflammatory cytokines like IL-7 and IL-15 for the treatment of ovarian cancer. Complementing this, ERNA-102 is another iMSC designed to deliver the anti-inflammatory cytokine IL-10, targeting rheumatoid arthritis.

Ernexa Therapeutics has secured a licensing agreement with Factor Bioscience Limited. The company, founded in 2018 and headquartered in Cambridge, Massachusetts, was formerly named Eterna Therapeutics Inc., before officially changing to Ernexa Therapeutics in March 2025.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Ernexa Therapeutics Inc. Warrants. Starting points for Ernexa Therapeutics Inc. Warrants: EPS -$8.95, beta 2.74 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Ernexa Therapeutics Inc. Warrants. Trailing twelve-month EPS for Ernexa Therapeutics Inc. Warrants stands at -$8.95. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
More →

Earnings per share estimates

Per shareThis yearYear to Dec 2025Next yearYear to Dec 2026
Average estimate−$4,050.00−$18.02
Lowest estimate−$4,050.00−$18.02
Highest estimate−$4,050.00−$18.02
Number of analysts11
A year ago——
Growth vs a year ago——

Revenue estimates

TotalThis yearYear to Dec 2025Next yearYear to Dec 2026
Average estimate$32.81M$75.35M
Lowest estimate$32.81M$75.35M
Highest estimate$32.81M$75.35M
Number of analysts11
A year ago——
Growth vs a year ago——

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Ernexa Therapeutics Inc. Warrants. Ernexa Therapeutics Inc. Warrants has reported as a listed company since 2024. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ERNAW12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
BNTXBioNTech SEHealthcareNASDAQ$20.1B
BOLDBoundless Bio, Inc.HealthcareNASDAQ$54.8M
BOLTBolt Biotherapeutics, Inc.HealthcareNASDAQ$12.8M
BOT.AXBotanix Pharmaceuticals LimitedHealthcareASX—
BOVNFBioInvent International AB (publ)HealthcareOTC$216.4M
BPMUFBasilea Pharmaceutica AGHealthcareOTC$871.3M
BPTHBio-Path Holdings, Inc.HealthcareOTC$554,529
BPTSYBiophytis S.A.HealthcareOTC$189,402
BRAXFBraxia Scientific Corp.HealthcareOTC$30,017
BRCTFBioArctic AB (publ)HealthcareOTC$3.4B
BRIBFBrii Biosciences LimitedHealthcareOTC$135.7M
BRNSBarinthus Biotherapeutics plcHealthcareNASDAQ$30.2M
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Ernexa Therapeutics Inc. Warrants executives and directors. Shares of Ernexa Therapeutics Inc. Warrants have traded between $0.04 and $0.08 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Ernexa Therapeutics Inc. Warrants.

ERNAW AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1